PRELUDE THERAPEUTICS INC Finance Lease, Principal Payments
PRELUDE THERAPEUTICS INC (PRLD) reported Finance Lease, Principal Payments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC finance lease, principal payments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC finance lease, principal payments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC finance lease, principal payments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC finance lease, principal payments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC finance lease, principal payments for fiscal 2025 was $208.00K, a 47.34% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC finance lease, principal payments for fiscal 2024 was $395.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $53.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $53.00K derived: sum of 3 quarters · filed 2026-08-11 | $208.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $53.00K derived: sum of 2 quarters · filed 2026-08-11 | $208.00K 10-Q · filed 2025-11-12 | $359.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $208.00K 10-Q · filed 2026-08-11 | $359.00K derived: sum of 3 quarters · filed 2026-08-11 | $507.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $155.00K 10-Q · filed 2026-05-12 | $306.00K derived: sum of 2 quarters · filed 2026-05-12 | $454.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $299.00K derived: sum of 2 quarters · filed 2026-03-10 | $395.00K 10-K · filed 2026-03-10 | |
| 2024-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $244.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $96.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |